Adenocarcinoma, Carcinoma, Uterine Cervix Adenosquamous Carcinoma
Conditions
Keywords
carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma
Brief summary
The primary study objective will be to assess the efficacy of the combination of radiation therapy with nimotuzumab and cisplatin, as compared to the combination of radiation therapy plus cisplatin in the treatment of Uterine Cervical Carcinoma (UCC). The secondary study objectives will be safety and tolerability evaluations, to determine treatment feasibility and the interim efficacy evaluation according to other parameters routinely used in oncology.
Detailed description
This will be a phase II, randomized, controlled, open-label, multicenter, and two-arm study. The study will be conducted in Brazil and has the purpose of determining the activity and safety of nimotuzumab in terms of overall and distant disease-free survival, radiological and clinical gynecological examinations, as well as by biopsy, if indicated, progression-free survival, local control of long-term disease, frequency of treatment-emergent adverse events, frequency of severe treatment-emergent adverse events. All participating patients will sign a consent form before they undergo any study-related procedure.The eligible patients will have stage IB and IVA uterine cervical carcinoma and they will be randomized to one of two treatment groups. Randomization and treatment assignment will be performed by a company specifically contracted for such purpose and will be per research site and disease stage (IB2 to IIIA versus IIIB to IVA), 1:1.
Interventions
DRUGNimotuzumab
Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
DRUGCisplatin
Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
RADIATIONBrachytherapy
Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks. Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week.
RADIATIONRadiation Therapy
Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week. Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week. Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week
Sponsors
Eurofarma Laboratorios S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years; * Diagnosis of histologically confirmed stages IB2 (\> 4 cm) to IVA prickle-cell carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma, according to FIGO system,7 (see Appendix A for guidance about staging); * Measurable disease according to RECIST 1.139 or at least disease evaluable through imaging methods and/or gynecological examination (magnetic resonance imaging (MRI) scans within six weeks prior to randomization will be accepted, computed tomography will accepted in case MRI is contraindicated); * Indication of definitive treatment with chemotherapy and radiation therapy, at the investigator's discretion; * Performance status \< 2, according to the Eastern Cooperative Oncology Group criteria 40 (ECOG; see Appendix C); * Adequate body functions, indicated by:Serum creatinine \< 1.2 mg/100 mL; Creatinine clearance \> 60 mL/min (estimate); Bilirubin up to 1.5-fold the upper limit of normal (ULN) and transaminases, alkaline phosphatase and gamma-glutamyltransferase up to 2.5-fold the ULN; Leucocytes \> 3,000/μL; Neutrophils \> 1,500/μL; Hemoglobin \> 10 g/dL; Platelets \> 80,000/μL; * Signed informed consent form.
Exclusion criteria
* Para-aortic lymph nodes involvement through radiological and/or surgical staging, at investigator's discretion; * Current severe comorbidity that, in the investigator's opinion, would put the patient at a significantly higher risk or will jeopardize protocol compliance; * Current bowel inflammatory disease; * Current major neurological or psychiatric disease, including clinically significant dementia and seizures, at the investigator's discretion; * Known hypersensitivity or allergic reactions to study treatment; * Current uncontrolled hypercalcemia (\> 11,5 mg/dL, that is, grade \> 1 according to Common Terminology Criteria for Adverse Events \[CTCAE\] v4.02, of US National Cancer Institute)41; * Know HIV positive status (enrollment of patients with hepatitis B or C is at the investigator's discretion); * Pregnancy or lactation; * Female patients, as well as their partners, who wish to become pregnant or are unwilling to use an appropriate contraceptive method throughout the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local control of disease | 1 year | Local control of disease will be measured by magnetic resonance imaging (MRI), clinical gynecological examinations, as well as by biopsy (if indicated), 12 weeks after treatment end. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete clinical response rate | 3 years | * Overall survival; * Distant disease-free survival; * Progression-free survival; * Local control of long-term disease; Frequency of treatment-emergent adverse events; o Frequency of severe treatment-emergent adverse events. |
Countries
Brazil
Outcome results
None listed